ESMO’s flagship annual congress has just taken place in Barcelona, once again laying down new markers of hope for the future of oncology. The meeting provided the usual mix of breakthrough science, ...

Investigators assessed whether intravesical BCG is necessary for patients with high-grade T1 nonmuscle-invasive bladder cancer who have unremarkable histology on the second transurethral resection.

Evidence suggests that combining metformin with standard of care could increase survival and offer other benefits to patients with high-volume disease.

Mid-stage data reported at the ESMO congress in Barcelona showed that ponsegromab was able to increase weight by 5.6% at the most effective dose, above the 5% threshold deemed clinically ...

The results of the GALAXIES Lung-02 study reported at the ESMO congress in Barcelona showed that the drug – added to GSK's PD-1 inhibitor Jemperli (dostarlimab) – achieved a higher objective ...

News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the third quarter ended September 30, 2024, and provided recent business ...

In an interview with Targeted Oncology, Peter Schmid, MD, PhD, discussed the results from the phase 3 KEYNOTE-522 trial.

SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ...

At the ESMO 2024 annual meeting in Barcelona, Spain, the results of numerous practice-changing trials were presented, including those from three highly-anticipated clinical trials in the advanced ...